Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437195 | 0.81 | CNR1 (0.42) | CHRM1ROCK2CNR1CNR2KDM4C | |
| SCHEMBL24437154 | 0.81 | DYRK1A (0.49) | CHRM1ROCK2CNR1CNR2KDM4C | |
| SCHEMBL24437153 | 0.80 | FABP3 (0.40) | CNR1CNR2MAPT | |
| SCHEMBL24437274 | 0.79 | CNR1 (0.51) | CNR1CNR2 | |
| SCHEMBL24437333 | 0.78 | WNT1 (0.39) | OPRM1OPRL1ROCK2KDM4CWNT1 | |
| SCHEMBL24437314 | 0.77 | KDM4C (0.40) | OPRM1OPRL1ROCK2KDM4CWNT1 | |
| SCHEMBL24437323 | 0.77 | PDE6D (0.42) | CHRM1CNR1CNR2 | |
| SCHEMBL24437144 | 0.77 | CNR1 (0.54) | OPRM1OPRL1CNR1CNR2 | |
| SCHEMBL24437232 | 0.77 | HTR3A (0.46) | CNR1CNR2 | |
| SCHEMBL24437269 | 0.71 | HIF1A (0.42) | OPRM1OPRL1ROCK2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | CHRM1 2817/4885OPRM1 1031/4885OPRL1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.